Latest news with #BachemHoldingAG
Yahoo
03-06-2025
- Business
- Yahoo
Bachem Mourns the Loss of Company Founder Dr. H.C. Peter Grogg
Bubendorf, Switzerland--(Newsfile Corp. - June 3, 2025) - The founder and honorary chairman of Bachem (SIX: BANB) Peter Grogg, passed away on Monday, June 2, 2025, at the age of 83. Peter Grogg founded Bachem in 1971 and built the company from a two-person operation into the global market leader for the chemical synthesis of peptides. Peter Grogg was CEO of the company for over 30 years until 2002 and Chairman of the Board of Directors of Bachem Holding AG until 2012. His daughter Nicole Grogg Hötzer has served as Vice-Chairwoman of the Board since 2011. For his achievements and merits in the field of peptides, Peter Grogg was awarded an honorary doctorate by the University of Basel. Kuno Sommer, Chairman of the Board of Directors of Bachem: "With Peter Grogg, we have lost a great entrepreneur. His drive and values made Bachem an internationally successful company and have left a lasting mark on it. In doing so, he has written a chapter of Swiss economic history. On behalf of the Board of Directors, the Executive Committee, and all employees of Bachem, I would like to express our deepest condolences to his wife, his two children, and their families." About Bachem Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with its headquarters in Switzerland and sites in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see For more information: Media Dr. Daniel Grotzky Head Group Communications Tel.: +41 58 595 2021 Email: media@ Investors Barbora Blaha Head Investor Relations Tel.: +41 58 595 0573Email: ir@ This publication may contain specific forward-looking statements, e.g. statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Bachem Holding AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Bachem Holding AG assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments. To view the source version of this press release, please visit Sign in to access your portfolio
Globe and Mail
30-04-2025
- Business
- Globe and Mail
Bachem Annual General Meeting 2025
All proposals of the Board of Directors approved. Dividend of CHF 0.85 per share. Bubendorf, Switzerland--(Newsfile Corp. - April 30, 2025) - Bachem Holding AG (SIX: BANB) ('Bachem') announced today that its Annual General Meeting 2025 has approved all proposals of the Board of Directors. A total of 79.7% of the 74'977'940 eligible shares were present. The Annual General Meeting approved a dividend of CHF 0.85 per share. The dividend will be paid on May 7, 2025. The last trading day entitling to receive the dividend is May 2, 2025. As of May 5, 2025, the shares will be traded ex-dividend. Both the Chairman and the other members of the Board of Directors were re-elected for a further year. Dr. Simone Wyss Fedele was elected as a new member of the Board. The existing members of the Compensation Committee were also re-elected for a further year. The shareholders approved the annual report, the financial statements of Bachem Holding AG, the consolidated financial statements for the business year 2024, as well as the appropriation of retained earnings and reserves from capital contributions and the total amount of the annual compensation paid to the Board of Directors and to the Corporate Executive Committee. Further, the shareholders approved the sustainability report and, in a consultative vote, the remuneration report. Forvis Mazars SA, Zurich was appointed by the Annual General Meeting as auditor of Bachem Holding AG for the business year 2025. A detailed list of all resolutions will be made available at Financial Calendar May 7, 2025 Payout date for dividend July 24, 2025 Publication of Half-Year Report 2025 March 12, 2026 Publication of Annual Report 2025; Media and Analyst conference April 29, 2026 Annual General Meeting (financial year 2025) About Bachem Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with its headquarters in Switzerland and sites in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see This publication may contain specific forward-looking statements, e.g. statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Bachem Holding AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Bachem Holding AG assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments. To view the source version of this press release, please visit
Business Insider
24-04-2025
- Business
- Business Insider
RBC Capital Remains a Buy on Bachem Holding AG (0QND)
RBC Capital analyst Charles Weston maintained a Buy rating on Bachem Holding AG (0QND – Research Report) on April 22 and set a price target of CHF78.00. The company's shares closed yesterday at CHF49.06. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. According to TipRanks, Weston is an analyst with an average return of -11.9% and a 26.47% success rate. Currently, the analyst consensus on Bachem Holding AG is a Moderate Buy with an average price target of CHF67.40. Based on Bachem Holding AG's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of CHF240.31 million and a net profit of CHF36.16 million. In comparison, last year the company earned a revenue of CHF239.86 million and had a net profit of CHF34.45 million
Yahoo
01-03-2025
- Business
- Yahoo
Solid Earnings May Not Tell The Whole Story For Bachem Holding (VTX:BANB)
Bachem Holding AG's (VTX:BANB) robust recent earnings didn't do much to move the stock. We think this is due to investors looking beyond the statutory profits and being concerned with what they see. See our latest analysis for Bachem Holding In high finance, the key ratio used to measure how well a company converts reported profits into free cash flow (FCF) is the accrual ratio (from cashflow). The accrual ratio subtracts the FCF from the profit for a given period, and divides the result by the average operating assets of the company over that time. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'. Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. While it's not a problem to have a positive accrual ratio, indicating a certain level of non-cash profits, a high accrual ratio is arguably a bad thing, because it indicates paper profits are not matched by cash flow. Notably, there is some academic evidence that suggests that a high accrual ratio is a bad sign for near-term profits, generally speaking. Over the twelve months to December 2024, Bachem Holding recorded an accrual ratio of 0.22. Unfortunately, that means its free cash flow fell significantly short of its reported profits. Even though it reported a profit of CHF120.2m, a look at free cash flow indicates it actually burnt through CHF138m in the last year. Coming off the back of negative free cash flow last year, we imagine some shareholders might wonder if its cash burn of CHF138m, this year, indicates high risk. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Bachem Holding's accrual ratio for the last twelve months signifies cash conversion is less than ideal, which is a negative when it comes to our view of its earnings. Because of this, we think that it may be that Bachem Holding's statutory profits are better than its underlying earnings power. But at least holders can take some solace from the 7.1% EPS growth in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. Every company has risks, and we've spotted 1 warning sign for Bachem Holding you should know about. This note has only looked at a single factor that sheds light on the nature of Bachem Holding's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
